ClinicalTrials.gg
Status unknownNCT00669747Updated Oct 2, 2008

Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)

A Phase 2 interventional study of Carboplatin i.d. Days 1 & 15 and Carboplatin i.d. Day 1; Normal Saline i.d. Day 15 in Ductal Carcinoma In Situ, sponsored by Windy Hill Medical, Inc.. Status unknown at 2 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-10-02.

Sponsored by Windy Hill Medical, Inc. · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2008), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States — 31 open to participants now, 51 under way, 6 of them phase 3. Carcinoma, Intraductal, Noninfiltrating · United States.

Planned enrollment
96th of 171
45 · median 51
Started
2008
with 14 others
Phase 2
60 of 210
9 open now
Registered
45th of 210
by date

Among the 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States, this one is the 96th largest by planned enrollment of the 171 interventional ones that give a count, is one of 15 that started in 2008, is one of 60 in phase 2, and was the 45th registered.

Carcinoma, Intraductal, Noninfiltrating

287 studies on the registry are indexed under Carcinoma, Intraductal, Noninfiltrating; 56 are open to participants now.

Browse Carcinoma, Intraductal, Noninfiltrating studies →

Open to participants now

31 of the 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 42 Carcinoma, Intraductal, Noninfiltrating studies recruiting now, 33 (79%) set no upper age limit and 5 (12%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 210 studies in Carcinoma, Intraductal, Noninfiltrating with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to compare the safety of 100 mg carboplatin administered intraductally once on Day 1 or twice on Days 1 and 15 in women with ductal carcinoma in situ (DCIS) undergoing surgical management 2 to 4 weeks following the Day 15 intraductal infusion. Secondary objectives are to characterize the biologic and clinical effects with respect to: pharmacokinetics, extent of disease on MRI and mammogram, histopathological assessment of DCIS, and biomarker measurement of Ki-67, TUNEL and G-actin.

Read the detailed description

This is a randomized, 3-arm, saline-controlled study involving women undergoing surgical management of DCIS. Forty-five (45) women who have been diagnosed with DCIS by core biopsy will receive intraductal administration of either carboplatin or normal saline (NS) into the DCIS-involved breast duct. Thirty (30) patients (i.e., 15 patients per arm) will receive two intraductal infusions of either 100 mg of carboplatin or NS on Days 1 and 15. Fifteen (15) patients will receive an intraductal infusion of 100 mg carboplatin on Day 1 and an intraductal infusion of NS on Day 15. Patients will undergo surgical resection 2 to 4 weeks following the Day 15 intraductal infusion (i.e. 4 to 6 weeks from diagnosis).

The effect of carboplatin on DCIS in the pre-treatment core biopsy specimen and the resection specimen will be assessed. Venous blood samples will be collected for carboplatin PK analysis pre-dose and at 30 minutes, 1, 2, 4, and 8 hours following intraductal infusions on Days 1 and 15.

03

Conditions studied

  • Ductal Carcinoma In Situ

Keywords

  • Ductal Carcinoma In Situ
  • DCIS
  • Breast Cancer
  • Carboplatin
  • Intraductal
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female
  • 18 years of age or older
  • Scheduled to undergo surgical resection in 2 weeks or longer
  • Pathological diagnosis of DCIS requiring surgical resection
  • DCIS diagnosed with core
  • Mammogram within 6 weeks of diagnosis
  • Adequate organ function as defined by the following criteria:

(ANC) ≥ 1500/μl, ≥ 140,000/μl, ≥ 12.0 g/dl, Creatinine \< 2.0 mg/dl

  • Able to sign

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of invasive or inflammatory breast carcinoma
  • DCIS with microinvasion on histology on core needle
  • Palpable mass
  • Mass on mammography
  • Concurrent anti-cancer therapy
  • Prior exposure to carboplatin (related to current or past diagnosis)
  • Prior radiation to the breast or chest wall
  • Prior areolar or breast surgery which interrupts communication of the ductal systems with the nipple
  • Presence of breast implants
  • Presence of ulcerating or fungal skin lesions or infection of the breasts
  • Pregnant or lactating
  • Impaired cardiac function or history of cardiac problems
  • Poor nutritional state (as determined by clinician)
  • Presence of serious infection
  • Scheduled for intraoperative radiation of breast or chest wall
  • Allergies to lidocaine or marcaine
  • Allergies to imaging dyes
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    A

    Carboplatin infused into DCIS-involved duct on Days 1 \& 15

    Drug: Carboplatin i.d. Days 1 & 15

  • Experimental
    B

    Carboplatin infused into DCIS-involved duct Day 1 and Normal Saline infused into DCIS-involved duct on Day 15

    Drug: Carboplatin i.d. Day 1; Normal Saline i.d. Day 15

  • Placebo comparator
    C

    Normal Saline infused into DCIS-involved duct Days 1 \& 15

    Drug: Normal Saline

Interventions

  • Carboplatin, 10 mg/ml, 10 ml (100 mg) infused into DCIS-involved duct on Days 1 \& 15

    Also known as: Paraplatin

  • Carboplatin 10 mg/ml, 10 ml (100 mg) i.d. DCIS duct on Day 1 Normal Saline, 10 ml i.d. DCIS duct on Day 15

    Also known as: Paraplatin

  • DrugNormal Saline

    Normal Saline, 10 ml, i.d. on Days 1 and 15

06

What researchers measure

Primary outcomes

  1. Compare the safety of 100 mg carboplatin administered intraductally once on Day 1 or twice on Days 1 and 15 in women with ductal carcinoma in situ (DCIS) undergoing surgical management 2 to 4 weeks following the Day 15 intraductal infusion

    Time frame: 2 to 4 weeks following the Day 15 intraductal infusion

Secondary outcomes

  1. characterize i.d. carboplatin pharmacokinetics

    Time frame: 4 -8 weeks

  2. characterize clinical extent of disease on MRI and/or mammogram

    Time frame: 2 - 4 weeks

  3. characterize the histopathological assessment of DCIS

    Time frame: 4 - 10 weeks

  4. Biomarker measurement of Ki-67, TUNEL and G-actin

    Time frame: 4 - 8 weeks

07

Study locations

2 of 2 sites recruiting
  • OU Medical Center Laboratory
    Oklahoma City, Oklahoma 73104, United States
    Recruiting
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
08

References and documents

Publications

  • Love SM, Barsky SH. Anatomy of the nipple and breast ducts revisited. Cancer. 2004 Nov 1;101(9):1947-57. doi: 10.1002/cncr.20559. PubMed 15382093 ↗
  • Li CI, Daling JR, Malone KE. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):1008-11. doi: 10.1158/1055-9965.EPI-04-0849. PubMed 15824180 ↗
  • Khan SA, Wiley EL, Rodriguez N, Baird C, Ramakrishnan R, Nayar R, Bryk M, Bethke KB, Staradub VL, Wolfman J, Rademaker A, Ljung BM, Morrow M. Ductal lavage findings in women with known breast cancer undergoing mastectomy. J Natl Cancer Inst. 2004 Oct 20;96(20):1510-7. doi: 10.1093/jnci/djh283. PubMed 15494601 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Sep 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2008
First posted
Apr 30, 2008
Start
May 2008
Primary completionEst.
Sep 2009
CompletionEst.
Dec 2009
Last update
Oct 2, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00669747
Lead sponsor
Windy Hill Medical, Inc.
First posted
Apr 30, 2008
Start date
May 2008
Primary completion
Sep 2009 (estimated)
Completion
Dec 2009 (estimated)
Last update
Oct 2, 2008

Study contacts

Jane Doerr, RN, MSN
Contact
jdoerr@whmed.com
949-636-4737
Andy Dorr, MD
Contact
andy.dorr@whmed.com
949-584-4975
Jane Doerr, RN, MSN
study director · Windy Hill Medical, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carboplatin

Start the discussion